Drugs that contain Sacubitril; Valsartan

1. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877938 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(4 years from now)

CN101098689A NOVARTIS PHARMS CORP Medicinal Combination Product Of Angiotensin Receptor Antagonist And Nep Inhibitor
Nov, 2026

(4 years from now)

CN102702119B NOVARTIS PHARMS CORP Pharmaceutical Composition Product With Angiotensin Receptor Antagonist And Nep Inhibitor
Nov, 2026

(4 years from now)

CN101098689B NOVARTIS PHARMS CORP Pharmaceutical Composition Product With Angiotensin Receptor Antagonist And Nep Inhibitor
Nov, 2026

(4 years from now)

CN102702119A NOVARTIS PHARMS CORP Pharmaceutical Composition Product With Angiotensin Receptor Antagonist And Nep Inhibitor
Nov, 2026

(4 years from now)

EP1948158B1 NOVARTIS PHARMS CORP Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor
Nov, 2026

(4 years from now)

EP1948158A1 NOVARTIS PHARMS CORP Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor
Nov, 2026

(4 years from now)

EP2340828B1 NOVARTIS PHARMS CORP Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And A Nep Inhibitor
Nov, 2026

(4 years from now)

EP2340828A1 NOVARTIS PHARMS CORP Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And A Nep Inhibitor
Nov, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404744 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jan, 2023

(3 months from now)

US8796331 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jan, 2023

(3 months from now)

US8404744

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jul, 2023

(9 months from now)

US8796331

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jul, 2023

(9 months from now)

US7468390 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Nov, 2023

(1 year, 1 month from now)

US7468390

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition May, 2024

(1 year, 7 months from now)

US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jan, 2025

(2 years from now)

US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jul, 2025

(2 years from now)

US9388134 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations Nov, 2026

(4 years from now)

US9388134

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations May, 2027

(4 years from now)

US8877938

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations Nov, 2027

(5 years from now)

US9937143 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033

(10 years from now)

US9517226 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033

(10 years from now)

US11135192 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033

(10 years from now)

US11058667 NOVARTIS PHARMS CORP Sacubitril-valsartan dosage regimen for treating heart failure May, 2036

(13 years from now)

Treatment: Treatment of heart failure; Treatment of heart failure with preserved ejection fraction; Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.